Pfizer tests new pill form of COVID drug in healthy people
NCT ID NCT07552779
First seen Apr 30, 2026 · Last updated May 07, 2026 · Updated 1 time
Summary
This early-stage study tests a new tablet form of the experimental COVID-19 drug ibuzatrelvir in 18 healthy adults. Researchers want to see how much of the drug gets into the blood with the new tablet compared to the original, and whether taking it with food or as a drink changes absorption. Participants stay in a clinic for about 10 days and are followed for 11 weeks. This study does not treat or prevent COVID-19.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer Clinical Research Unit - Brussels
RECRUITINGBrussels, Bruxelles-capitale, Région de, B-1070, Belgium
Conditions
Explore the condition pages connected to this study.